
    
      The aim of this clinical investigation is to evaluate if the use of XonridÂ® in the prevention
      and treatment of G2 radiation dermatitis in breast and head & neck cancer patients can be a
      valid support, when compared to the Standard of Care as defined by MASCC (Multinational
      Association for Supportive Care in Cancer) guidelines.
    
  